Plain-English translation of NCT06811116 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether combining two medications — and cabozantinib — works better than cabozantinib alone for treating advanced liver cancer in patients whose cancer cells have a specific genetic change in a gene called β-catenin. The first part of the trial will figure out the safest dose of this medication combination, and the second part will compare how well the combination works versus the standard treatment alone.
Liver cancer with this particular genetic change doesn't respond well to current treatments, and doctors need better options for patients whose cancer has already spread or cannot be surgically removed. This trial is exploring whether adding the new medication to existing treatment might help patients live longer and keep their cancer from growing.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will take pills by mouth every day as part of a 28-day cycle that repeats until your cancer stops responding or side effects become too difficult. You will have regular blood draws and imaging scans (CT, MRI, or X-rays) throughout the study to monitor how well the medication is working. The trial has two phases: the first determines the safest dose, and the second randomly assigns participants to either receive the medication combination or the standard treatment alone.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
United States